MX2022011974A - Composiciones y metodos para neutralizar la toxicidad de los lipopolisacaridos y metodos para identificar estos. - Google Patents

Composiciones y metodos para neutralizar la toxicidad de los lipopolisacaridos y metodos para identificar estos.

Info

Publication number
MX2022011974A
MX2022011974A MX2022011974A MX2022011974A MX2022011974A MX 2022011974 A MX2022011974 A MX 2022011974A MX 2022011974 A MX2022011974 A MX 2022011974A MX 2022011974 A MX2022011974 A MX 2022011974A MX 2022011974 A MX2022011974 A MX 2022011974A
Authority
MX
Mexico
Prior art keywords
methods
lipopolysaccharide
toxicity
compositions
identifying
Prior art date
Application number
MX2022011974A
Other languages
English (en)
Inventor
James Masters
Harsh Mahendra Trivedi
Dandan Chen
Original Assignee
Colgate Palmolive Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Colgate Palmolive Co filed Critical Colgate Palmolive Co
Publication of MX2022011974A publication Critical patent/MX2022011974A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/50—Lipopolysaccharides; LPS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Abstract

Se describen métodos para identificar una composición que neutraliza la toxicidad de un lipopolisacárido. Los métodos comprenden comparar la cantidad de citocina y/o prostaglandina E2 secretada por células que tienen receptores de tipo toll activados por un lipopolisacárido en presencia o ausencia de una composición de prueba. También se describen métodos para neutralizar la toxicidad de un lipopolisacárido en la cavidad bucal de un individuo mediante el uso de composiciones para neutralizar toxicidad identificada de un lipopolisacárido. También se describe el método para neutralizar la toxicidad de un lipopolisacárido en la cavidad bucal de un individuo mediante el uso de composiciones para el cuidado bucal que comprenden combinaciones de óxido de zinc y citrato de zinc.
MX2022011974A 2020-04-02 2021-04-02 Composiciones y metodos para neutralizar la toxicidad de los lipopolisacaridos y metodos para identificar estos. MX2022011974A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063004174P 2020-04-02 2020-04-02
US202163200318P 2021-03-01 2021-03-01
PCT/US2021/070350 WO2021203142A1 (en) 2020-04-02 2021-04-02 Compositions for and methods of neutralizing lipopolysaccharide toxicity and methods of identifying the same

Publications (1)

Publication Number Publication Date
MX2022011974A true MX2022011974A (es) 2022-10-20

Family

ID=75919473

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011974A MX2022011974A (es) 2020-04-02 2021-04-02 Composiciones y metodos para neutralizar la toxicidad de los lipopolisacaridos y metodos para identificar estos.

Country Status (6)

Country Link
US (1) US20210318306A1 (es)
EP (1) EP4018196A1 (es)
CN (1) CN115298546A (es)
CA (1) CA3177046A1 (es)
MX (1) MX2022011974A (es)
WO (1) WO2021203142A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8283135B2 (en) * 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
ES2431291T3 (es) * 2006-01-10 2013-11-25 Colgate-Palmolive Company Métodos para modular receptores de superficie celular para prevenir o reducir la inflamación
CN104822362A (zh) 2012-12-05 2015-08-05 高露洁-棕榄公司 氟化物稳定的含锌组合物
MX367481B (es) * 2013-12-02 2019-08-23 Colgate Palmolive Co Composiciones con zinc para el cuidado oral.
CN104721226B (zh) 2013-12-19 2019-12-24 高露洁-棕榄公司 口腔护理组合物
MX2017014196A (es) * 2015-05-06 2018-03-01 Procter & Gamble Deteccion de factores de virulencia microbiana bucal.
WO2017003856A1 (en) 2015-07-01 2017-01-05 Colgate-Palmolive Company Oral care compositions and methods of use
WO2017223169A1 (en) 2016-06-24 2017-12-28 Colgate-Palmolive Company Oral care compositions and methods of use

Also Published As

Publication number Publication date
US20210318306A1 (en) 2021-10-14
CA3177046A1 (en) 2021-10-07
WO2021203142A1 (en) 2021-10-07
CN115298546A (zh) 2022-11-04
EP4018196A1 (en) 2022-06-29

Similar Documents

Publication Publication Date Title
Yassen et al. Bovine teeth as substitute for human teeth in dental research: a review of literature
DK2198876T3 (da) Fremgangsmåde til nedsættelse af sandsynligheden for implantationssvigt i et individ
SG169990A1 (en) Improved oral compositions comprising zinc citrate and/or tocopherol agents
MX2007002722A (es) Composicion acondiciondora para el cuidado del cabello.
MX2021007534A (es) Metodos para cambiar la biopelicula en la cavidad bucal de biopeliculas patogenas a sanas.
EP1774332A4 (en) METHOD FOR ASSESSING IMMUNO REACTIONS
MY157914A (en) Oral compositions comprising siloxane polymers
MX2019013485A (es) Composiciones para el cuidado bucal y metodos de uso.
MX2022011974A (es) Composiciones y metodos para neutralizar la toxicidad de los lipopolisacaridos y metodos para identificar estos.
CO2022013251A2 (es) Formulaciones de anticuerpos anti-tslp humanos y métodos de uso de los mismos
MX2020013510A (es) Composiciones para tratamiento, y metodos para fabricar y usar las mismas.
MX2007009238A (es) Pasta de dientes.
AR078772A1 (es) Composicion para el cuidado bucal que comprende serina y uno o mas agentes quelantes
CL2019003011A1 (es) Composiciones para el cuidado bucal a base de oxido de cinc y fosfato de dihidrógeno de calcio.
EA200701598A1 (ru) Способ и композиция для восстановления эпителиальных и других клеток и тканей
MX2021011355A (es) Composicion para cuidado oral.
MX2021007609A (es) Composiciones para el cuidado bucal que comprenden un copolimero de injerto de polivinilo capralactam-polivinil acetato-polietilenglicol, y metodos para el mismo.
MX2022007261A (es) Composiciones para el cuidado oral y metodos de uso.
EP1224924A3 (de) Mischung zur Behandlung entzündlicher Zahnerkrankungen und zur Verwendung als Wurzelkanalfüllmaterial
MX2021012778A (es) Metodos y composiciones para reducir la tincion de composiciones antibacterianas para el cuidado bucal.
BR112021023760A2 (pt) Composição compreendendo colágeno, glicerol e edta, método de tratamento de uma condição de pele de um sujeito e kit
BR112022018770A2 (pt) Composição alogênica compreendendo células t vd1+, dose, e, método de tratamento de uma malignidade mieloide
CL2022001251A1 (es) Composiciones desodorantes.
WO2023122192A3 (en) Long-wear compositions containing acid-functional silicone elastomer and block copolymer
WO2023104086A3 (en) Oral care compositions with hyaluronic acid